IN2014MN00380A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00380A
IN2014MN00380A IN380MUN2014A IN2014MN00380A IN 2014MN00380 A IN2014MN00380 A IN 2014MN00380A IN 380MUN2014 A IN380MUN2014 A IN 380MUN2014A IN 2014MN00380 A IN2014MN00380 A IN 2014MN00380A
Authority
IN
India
Prior art keywords
comparising
nanoparticles
producing
composition
active compound
Prior art date
Application number
Other languages
English (en)
Inventor
Cammarano Raffaele
Meiser Felix
Postma Almar
Caruso Frank
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006903527A external-priority patent/AU2006903527A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of IN2014MN00380A publication Critical patent/IN2014MN00380A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IN380MUN2014 2006-06-30 2007-06-29 IN2014MN00380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006903527A AU2006903527A0 (en) 2006-06-30 Methods For The Preparation Of Pharmaceutically Active Compounds in Nanoparticulate Form
US91595507P 2007-05-04 2007-05-04
PCT/AU2007/000910 WO2008000042A1 (en) 2006-06-30 2007-06-29 Methods for the preparation of biologically active compounds in nanoparticulate form

Publications (1)

Publication Number Publication Date
IN2014MN00380A true IN2014MN00380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-19

Family

ID=38845051

Family Applications (1)

Application Number Title Priority Date Filing Date
IN380MUN2014 IN2014MN00380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-06-30 2007-06-29

Country Status (9)

Country Link
US (4) US20150164802A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2054042B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP5508003B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2007264418B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2653384C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2054042T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL195945A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MN00380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2008000042A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN00380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-06-30 2015-06-19 Iceutica Pty Ltd
CN107049957A (zh) * 2009-04-24 2017-08-18 伊休蒂卡有限公司 包封的纳米颗粒在工业规模的制备
AU2014208310C1 (en) * 2009-04-24 2020-01-23 Iceutica Pty Ltd A Novel Formulation of Diclofenac
CN102438592B (zh) * 2009-04-24 2016-09-14 伊休蒂卡有限公司 甲氧萘普酸的剂型
WO2010121320A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
CN104000785B (zh) * 2009-04-24 2021-01-05 伊休蒂卡有限公司 美他沙酮的新剂型
AU2014201967B2 (en) * 2009-04-24 2015-09-17 Iceutica Pty Ltd A Novel Formulation of Naproxen
KR20140077945A (ko) 2009-04-24 2014-06-24 아이슈티카 피티와이 리미티드 신규 인도메타신 제제
BRPI1014272A2 (pt) * 2009-04-24 2016-10-18 Iceutica Pty Ltd nova formulação de diclofenac
PH12015501811A1 (en) * 2009-04-24 2019-03-25 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
AU2014202776B2 (en) * 2009-04-24 2016-02-25 Iceutica Pty Ltd A Novel Formulation of Indomethacin
MA33294B1 (fr) * 2009-04-24 2012-05-02 Iceutica Pty Ltd Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
AP3659A (en) * 2009-04-24 2016-04-08 Iceutica Pty Ltd A novel formulation of meloxicam
MY163538A (en) * 2009-04-24 2017-09-15 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
AU2016200397B2 (en) * 2009-04-24 2017-08-17 Iceutica Pty Ltd A Novel Formulation of Indomethacin
WO2010146407A1 (en) * 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
JP5816194B2 (ja) * 2009-12-22 2015-11-18 レオ ファーマ アクティーゼルスカブ カルシポトリオール一水和物ナノクリスタル
US20120141589A1 (en) * 2010-08-23 2012-06-07 Basf Se Particles for drug delivery and other applications
WO2012027366A2 (en) 2010-08-23 2012-03-01 President And Fellows Of Harvard College Acoustic waves in microfluidics
WO2012085927A2 (en) * 2010-12-02 2012-06-28 Mylan Laboratories, Limited Tadalafil compositions
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
US9138381B2 (en) 2013-02-08 2015-09-22 Basf Se Production of inorganic-organic composite materials by reactive spray-drying
WO2014122077A1 (de) 2013-02-08 2014-08-14 Basf Se Herstellung von anorganisch-organischen kompositmaterialien durch reaktive sprühtrocknung
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
HU231309B1 (hu) * 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
KR101742152B1 (ko) * 2014-02-27 2017-06-01 바로돈에스에프주식회사 비특이성 면역증강제 조성물 및 그 제조방법, 그리고 그 용도
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2015200616A1 (en) 2014-06-26 2015-12-30 President And Fellows Of Harvard College Fluid injection using acoustic waves
AU2016311341B2 (en) 2015-08-27 2021-01-28 President And Fellows Of Harvard College Acoustic wave sorting
JP2019536787A (ja) * 2016-11-30 2019-12-19 ドラッガビリティ テクノロジーズ アイピー ホルコ リミテッドＤｒｕｇｇａｂｉｌｉｔｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ ＩＰ Ｈｏｌｄｃｏ Ｌｉｍｉｔｅｄ タダラフィルを含有する医薬製剤
US11701658B2 (en) 2019-08-09 2023-07-18 President And Fellows Of Harvard College Systems and methods for microfluidic particle selection, encapsulation, and injection using surface acoustic waves
US20230173073A1 (en) * 2020-06-25 2023-06-08 Omya International Ag Co-ground active(s) comprising product comprising surface-reacted calcium carbonate

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3312671A1 (de) 1983-04-08 1984-10-11 Heinz Finzer KG, 7880 Bad Säckingen Stanz- und biegewerkzeug-aggregat
GB8328929D0 (en) 1983-10-29 1983-11-30 Sterwin Ag Steroid compounds
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
CA2143263C (en) 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5631369A (en) 1994-08-31 1997-05-20 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
WO1997008950A1 (en) * 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
EP0930874A2 (en) * 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
ZA987800B (en) 1997-08-27 1999-06-09 Hexal Ag Pharmaceutical composition of meloxicam
PT1073417E (pt) 1998-04-18 2003-04-30 Glaxo Group Ltd Formulacao farmaceutica em aerossol
AUPP355798A0 (en) * 1998-05-15 1998-06-11 University Of Western Australia, The Process for the production of ultrafine powders
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1913939B1 (en) 2000-06-27 2017-05-31 Vectura Limited Formulations for use in inhaler devices
EP1313451B1 (en) * 2000-08-31 2009-03-11 Jagotec AG Milled particles
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4541647B2 (ja) * 2000-11-20 2010-09-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物
ATE517607T1 (de) 2000-11-30 2011-08-15 Vectura Ltd Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
WO2003063838A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
ITMI20021074A1 (it) 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US20070059356A1 (en) 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4123834B2 (ja) 2002-06-10 2008-07-23 株式会社ダイフク 移載設備
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
EP1832583A1 (en) 2002-09-30 2007-09-12 A/S GEA Farmaceutisk Fabrik Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
WO2004058216A2 (en) 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
DE602004018150D1 (de) 2003-08-08 2009-01-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
US20070071825A1 (en) 2003-10-01 2007-03-29 Catherine Curdy Device and method for making particles
WO2006009419A1 (es) 2004-07-19 2006-01-26 Luis Cordova Boone Neumáticos con doble banda de rodamiento
KR20060024927A (ko) 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
WO2006041843A2 (en) 2004-10-04 2006-04-20 Dr. Reddy's Laboratories Ltd. Pharmaceutical dosage form comprising meloxicam
CA2598204C (en) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
BRPI0518101A (pt) * 2004-12-31 2008-10-28 Iceutica Pty Ltd métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
WO2007070852A2 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
EP1978933A2 (en) 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
JP2009519972A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
NZ573823A (en) 2006-06-30 2012-05-25 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
IN2014MN00380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-06-30 2015-06-19 Iceutica Pty Ltd
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
US8568696B2 (en) 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
JP2010167968A (ja) 2009-01-23 2010-08-05 Mitsubishi Fuso Truck & Bus Corp 床構造
KR20140077945A (ko) 2009-04-24 2014-06-24 아이슈티카 피티와이 리미티드 신규 인도메타신 제제
MY163538A (en) 2009-04-24 2017-09-15 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
MA33294B1 (fr) 2009-04-24 2012-05-02 Iceutica Pty Ltd Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
CN102438592B (zh) 2009-04-24 2016-09-14 伊休蒂卡有限公司 甲氧萘普酸的剂型
WO2010121320A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
BRPI1014272A2 (pt) 2009-04-24 2016-10-18 Iceutica Pty Ltd nova formulação de diclofenac
CN104000785B (zh) 2009-04-24 2021-01-05 伊休蒂卡有限公司 美他沙酮的新剂型
AP3659A (en) 2009-04-24 2016-04-08 Iceutica Pty Ltd A novel formulation of meloxicam
CN107049957A (zh) 2009-04-24 2017-08-18 伊休蒂卡有限公司 包封的纳米颗粒在工业规模的制备

Also Published As

Publication number Publication date
IL195945A0 (en) 2009-09-01
US20220054418A1 (en) 2022-02-24
JP2016026220A (ja) 2016-02-12
JP6651489B2 (ja) 2020-02-19
US11103456B2 (en) 2021-08-31
US20150164802A1 (en) 2015-06-18
AU2007264418B2 (en) 2012-05-03
AU2007264418A1 (en) 2008-01-03
US20180369145A1 (en) 2018-12-27
JP2009541362A (ja) 2009-11-26
CA2653384C (en) 2017-03-14
EP2054042A4 (en) 2012-08-15
CA2960377A1 (en) 2008-01-03
US20240122855A1 (en) 2024-04-18
JP2018058846A (ja) 2018-04-12
JP5508003B2 (ja) 2014-05-28
EP2054042A1 (en) 2009-05-06
IL243534B (en) 2021-03-25
EP2054042B8 (en) 2020-06-10
DK2054042T3 (da) 2020-08-03
WO2008000042A1 (en) 2008-01-03
IL243534A0 (en) 2016-02-29
EP2054042B1 (en) 2020-04-29
CA2653384A1 (en) 2008-01-03
IL195945A (en) 2016-02-29
JP2014058524A (ja) 2014-04-03

Similar Documents

Publication Publication Date Title
IN2014MN00380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
AP2914A (en) Method for producing 4-oxoquinoline compound
UA103794C2 (en) Liposome composition
SG171584A1 (en) Nanoparticulate metal boride composition and its use for identification- marking plastic parts
EP2172462A4 (en) METHOD FOR PRODUCING A 3-HYDROXYPROPAN-1-ON COMPOUND, METHOD FOR PRODUCING A 2-PROPENE-1-ON COMPOUND, AND METHOD FOR PRODUCING AN ISOXAZOLINE COMPOUND
EP2260112A4 (en) SCREENING PROCESS FOR INDIVIDUAL CELLS FOR THE MANUFACTURE OF BIOLOGICAL ACTIVE SUBSTANCES
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
WO2008051465A3 (en) Process for making crystalline anhydrous docetaxel
NZ593874A (en) Nalmefene hydrochloride dihydrate
TN2012000248A1 (en) Novel spiropiperidine compounds
TR201910311T4 (tr) L-metiyonin öncüsü üreten mikroorganizma ve mikroorganizma kullanarak L-metiyonin öncüsü üretme yöntemi.
EP2060349A4 (en) METHOD FOR MANUFACTURING HOLE DISCHARGING
EP2132013A4 (en) THIN METAL NANODRESSES MANUFACTURED BY BIOTEMPLATING
SG143149A1 (en) Phosphite composition and method for producing the same
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
EP2103603A4 (en) PROCESS FOR PREPARING A PYRROLIDINE COMPOUND
IL192788A0 (en) Method for producing steroid compound
IL193137A0 (en) Method of characterizing a biologically active compound
EP2061778A4 (en) METHOD FOR PRODUCING A CYCLIC UNSATURATED COMPOUND
EP2261317B8 (en) Microorganism producing cyclic compound
IL192702A0 (en) Process for producing 5-alkoxy-4-hydroxymethylpyrazole compound
ZA200807547B (en) Method for producing 4-oxoquinoline compound
TW200740772A (en) Reduction of 5-(aryl-diazenyl)-4,6-dihalo-pyrimidine
EP2039698A4 (en) PHOSPHORUS MOLYBDENUM COMPOUND AND PROCESS FOR PRODUCING THE SAME